2024
Gene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes
Kiwan A, Kewan T, Xu M, Siddon A, Girardi M, Sethi T, Foss F. Gene Copy Number Alterations Identify Subsets of Mycosis Fungoides/Sézary Syndrome Patients with Worse Survival Outcomes. Blood 2024, 144: 4440-4440. DOI: 10.1182/blood-2024-205144.Peer-Reviewed Original ResearchGene copy number alterationsAssociated with poor OSAbsolute lymphocyte countFluorescence in situ hybridization panelAssociated with worse OSCirculating tumor cellsFluorescence in situ hybridizationOverall survivalCopy number alterationsT cell receptorPoor OSSurvival outcomesTumor cellsMedian OSCox proportional hazardsBlood involvementATM deletionArid1a deletionT cellsElevated absolute lymphocyte countMedian absolute lymphocyte countAssociated with better OSMedian age of patientsMultivariate CPH modelZEB1 deletionCirculating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer
Goldkorn A, Tangen C, Plets M, Bsteh D, Xu T, Pinski J, Ingles S, Triche T, MacVicar G, Vaena D, Crispino A, McConkey D, Lara P, Hussain M, Quinn D, Dorff T, Lerner S, Thompson I, Agarwal N. Circulating Tumor Cell Count and Overall Survival in Patients With Metastatic Hormone-Sensitive Prostate Cancer. JAMA Network Open 2024, 7: e2437871. PMID: 39374015, PMCID: PMC11581504, DOI: 10.1001/jamanetworkopen.2024.37871.Peer-Reviewed Original ResearchConceptsMetastatic hormone-sensitive prostate cancerMetastatic castration-resistant prostate cancerCirculating tumor cell countCirculating tumor cellsHormone-sensitive prostate cancerTumor cell countOverall survivalProstate cancerPrognostic valueCTC countsPrognostic factorsProgression to metastatic castration-resistant prostate cancerDiagnosed mHSPCPeripheral blood circulating tumor cellsClinical trialsBlood circulating tumor cellsCastration-resistant prostate cancerPrognostic studyCell countBaseline CTC countProgression-free survivalLines of therapyEnhanced overall survivalProstate-specific antigenIncreased prognostic valueSearching for the “Holy Grail” of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA)
Gao L, Medford A, Spring L, Bar Y, Hu B, Jimenez R, Isakoff S, Bardia A, Peppercorn J. Searching for the “Holy Grail” of breast cancer recurrence risk: a narrative review of the hunt for a better biomarker and the promise of circulating tumor DNA (ctDNA). Breast Cancer Research And Treatment 2024, 205: 211-226. PMID: 38355821, DOI: 10.1007/s10549-024-07253-6.Peer-Reviewed Original ResearchConceptsCirculating tumor DNABreast cancer careSystemic therapyTumor DNABreast cancerBreast cancer recurrence riskRisk of recurrenceCancer careCancer recurrence riskCirculating tumor cellsNarrative reviewTreat many patientsBreast cancer evaluationDistant diseaseFear of recurrenceBreast oncologistsPredictive biomarkersRecurrence riskTumor cellsCancer evaluationImprove prognosticationClinical challengeTreatment selectionPatientsBreast
2020
Prevalence and tissue concordance of BRCA2 copy number loss evaluated by single-cell, shallow whole genome sequencing of circulating tumor cells (CTCs) in castration-resistant prostate cancer (CRPC).
Barnett E, Schonhoft J, Schultz N, Lee J, Zaidi S, Abida W, Carmichael T, Dago A, Solit D, Wenstrup R, Scher H. Prevalence and tissue concordance of BRCA2 copy number loss evaluated by single-cell, shallow whole genome sequencing of circulating tumor cells (CTCs) in castration-resistant prostate cancer (CRPC). Journal Of Clinical Oncology 2020, 38: 5531-5531. DOI: 10.1200/jco.2020.38.15_suppl.5531.Peer-Reviewed Original ResearchPoly ADP-ribose polymerase inhibitorsCirculating tumor cellsCopy number variantsCastration-resistant prostate cancerCell-free DNACirculating tumor cell samplingInter-cellular heterogeneityDNA damage repairBRCA2 lossSource of genetic informationTumor cellsPoly ADP-ribose polymerase inhibitors therapyCopy number lossSource of tumor materialProstate cancer tissue specimensDetect circulating tumor cellsDNA damage repair deficiencyCTC-positive casesMetastatic CRPC patientsPre-treatment biopsiesCirculating tumor cell analysisGenome sequenceGenomic studiesCancer tissue specimensSequencing tissueCirculating tumor cells (CTCs) with small-cell like pathology are prevalent in metastatic castration-resistant prostate cancer (mCRPC) and show selective pharmacodynamic reductions in patients treated with platinum but not ARSI or taxane.
Scher H, Jendrisak A, Gill A, Barnett E, Gopalan A, Zaidi S, Benoliel H, Carbone E, Byun J, Schonhoft J, Wenstrup R. Circulating tumor cells (CTCs) with small-cell like pathology are prevalent in metastatic castration-resistant prostate cancer (mCRPC) and show selective pharmacodynamic reductions in patients treated with platinum but not ARSI or taxane. Journal Of Clinical Oncology 2020, 38: 5572-5572. DOI: 10.1200/jco.2020.38.15_suppl.5572.Peer-Reviewed Original ResearchMetastatic castration-resistant prostate cancerAndrogen receptor signaling axisCirculating tumor cellsPatients treated with platinumSmall-cell lung cancerCTC subtypesCastration-resistant prostate cancerCirculating tumor cells subtypesSmall-cell histologyPlatinum-based therapyAR protein expressionSmall-cell carcinomaAnalysis of circulating tumor cellsSmall-cell morphologyAnalytically validated assaysAssess drug activityLife-prolonging drugsCK+ cellsSmall cell/neuroendocrineTherapy linesOn-therapyProstate cancerPharmacodynamic changesTreated patientsTumor cells
2018
The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: A systematic review
Khetrapal P, Lee M, Tan W, Dong L, de Winter P, Feber A, Kelly J. The role of circulating tumour cells and nucleic acids in blood for the detection of bladder cancer: A systematic review. Cancer Treatment Reviews 2018, 66: 56-63. PMID: 29684744, DOI: 10.1016/j.ctrv.2018.03.007.Peer-Reviewed Original ResearchConceptsCirculating tumor cellsBladder cancerBlood-based biomarkersValidation cohortTumor cellsDiagnostic value of circulating tumor cellsCirculating tumor cell biomarkerDetection of bladder cancerSystematic reviewCell-free DNAIndependent validation cohortCirculating nucleic acidsSolid cancersAUC/ROC valueUrinary biomarkersMedian numberDiagnostic valueCancerBiomarker sensitivityBiomarkersNucleic acidsBladderSystematic searchCohortAUC/ROC
2015
Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells.
Williams E, Rodriguez-Bravo V, Chippada-Venkata U, De Ia Iglesia-Vicente J, Gong Y, Galsky M, Oh W, Cordon-Cardo C, Domingo-Domenech J. Generation of Prostate Cancer Patient Derived Xenograft Models from Circulating Tumor Cells. Journal Of Visualized Experiments 2015, 53182. PMID: 26555435, PMCID: PMC4692658, DOI: 10.3791/53182.Peer-Reviewed Original ResearchConceptsCirculating tumor cellsPDX modelsTumor cellsGeneration of PDX modelsProstate cancer patientsPreclinical drug evaluationProstate cancer researchPersonalized medicine strategiesPeripheral blood samplesExperimental modelCirculating tumor cell enrichmentModels of breastPositive mononuclear cellsCancer researchMetastatic diseaseProstate cancerImmunocompromised miceRed blood cell lysisTumor typesMononuclear cellsXenograft modelCancer patientsDisease stageBlood cell lysisTumor metastasisConsensus on biomarkers for neuroendocrine tumour disease
Oberg K, Modlin I, De Herder W, Pavel M, Klimstra D, Frilling A, Metz D, Heaney A, Kwekkeboom D, Strosberg J, Meyer T, Moss S, Washington K, Wolin E, Liu E, Goldenring J. Consensus on biomarkers for neuroendocrine tumour disease. The Lancet Oncology 2015, 16: e435-e446. PMID: 26370353, PMCID: PMC5023063, DOI: 10.1016/s1470-2045(15)00186-2.Peer-Reviewed Original ResearchConceptsNeuroendocrine tumorsManagement of neuroendocrine tumorsManagement of patientsCirculating tumor cellsNeuroendocrine tumor diseaseLack of treatment optionsNeuroendocrine neoplasiaBiomarker limitationsPrognostic markerTreatment optionsTumor cellsCurrent biomarkersClinical challengeTumorClinical useNovel biomarkersImaging modalitiesTumor diseaseConsensus meetingBiomarkersMonoanalytePoor sensitivityMultidisciplinary expertsDiseaseTreatment effects
2012
The Emerging Role of Circulating Tumor Cell Detection in Genitourinary Cancer
Small A, Gong Y, Oh W, Hall S, van Rijn C, Galsky M. The Emerging Role of Circulating Tumor Cell Detection in Genitourinary Cancer. Journal Of Urology 2012, 188: 21-26. PMID: 22578722, DOI: 10.1016/j.juro.2012.02.2558.Peer-Reviewed Original ResearchConceptsCirculating tumor cellsGenitourinary cancersTumor cellsTumor cell detectionCell carcinomaCirculating tumor cell capture technologiesSignificance of circulating tumor cellsCastration resistant prostate cancerReal-time liquid biopsyClinically localized cancerHeterogeneous natural historyCirculating tumor cell detectionResistant prostate cancerTransitional cell carcinomaTreatment response biomarkersRenal cell carcinomaClinical applicationPotential clinical applicationsMetastatic sitesPrimary tumorLocalized cancerProstate cancerCurative therapyPeripheral bloodMalignant cells
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply